Am. J. Respir. Crit. Care Med., Volume 156, Number 5, November 1997, 1662-1668

RhDNase I Aerosol Deposition and Related Factors in Cystic Fibrosis

PATRICE DIOT, LUCY B. PALMER, ARLENE SMALDONE, JOAN DECELIE-GERMANA, ROGER GRIMSON, and GERALD C. SMALDONE

Service de Pneumologie, Unite d'Evaluation Clinique, CHU Bretonneau Tours cedex, France; and Departments of Medicine, Pediatrics, and Preventative Medicine, State University of New York at Stony Brook, Stony Brook, New York

To identify factors influencing lung dose of aerosolized recombinant human deoxyribonuclease (rhDNase I), we used gamma camera and filter techniques to measure deposition in 15 clinically stable patients with cystic fibrosis (CF) (five males and 10 females, age 6-31 yr, mean 16.9) who were on chronic daily therapy. Total and regional deposition were correlated with breathing pattern, pulmonary function, demographic factors, and disease severity. In addition, the effects of each patient's measured lung dose on pulmonary function was estimated by stopping the drug and observing changes in spirometry over a 2-wk follow-up period. After discontinuance of the drug, all patients reported worsening of dyspnea and difficulty producing sputum. There was a significant decrease in FEV₁ (% predicted, mean ± SE, 86.9% ± 5.57 to 77.8% ± 5.73, p < 0.005), but all patients completed the study. In some patients, as much as 48% of the deposited aerosol was found in the pharynx (range 0.0 to 0.30 mg, mean 0.089 mg ± 0.029), and pharyngeal deposition correlated negatively with tidal volume (r = 0.696, p < 0.006) and age (r = 0.743, p < 0.005). For the lungs, deposition ranged between 0.16 mg and 0.78 mg of the 2.5 mg nebulizer dose (mean 0.47 ± 0.04 mg) and correlated negatively with FEV₁ (% predicted, r = 0.611, p = 0.0152). However, the spirometric decrements following cessation of therapy did not correlate with the lung dose of the drug. Analysis of regional deposition within the lungs indicated a wide range of distribution between central and peripheral zones. In conclusion, the deposition pattern of rhDNase l aerosols in patients with CF is largely influenced by respiratory physiology, which itself depends upon age and severity of lung disease. As the patients grow there is a decrease in upper airway deposition and more particles are presented to the lungs where those patients with more airways disease have enhanced pulmonary deposition. Upper airway deposition of rhDNase I is significant, especially in younger patients, and may be related to laryngeal side effects.

This article has been cited by other articles:

				K. W. Harris and G. C. Smaldone Facial and Ocular Deposition of Nebulized Budesonide: Effects of Face Mask Design Chest, February 1, 2008; 133(2): 482 - 488. [Abstract] [Full Text] [PDF]

				S. W. Stites, G. V. Perry, T. Peddicord, G. Cox, C. McMillan, and B. Becker Effect of High-Frequency Chest Wall Oscillation on the Central and Peripheral Distribution of Aerosolized Diethylene Triamine Penta-acetic Acid as Compared to Standard Chest Physiotherapy in Cystic Fibrosis Chest, March 1, 2006; 129(3): 712 - 717. [Abstract] [Full Text] [PDF]

				R. Condos, F. P. Hull, N. W. Schluger, W. N. Rom, and G. C. Smaldone Regional Deposition of Aerosolized Interferon-{gamma} in Pulmonary Tuberculosis Chest, June 1, 2004; 125(6): 2146 - 2155. [Abstract] [Full Text] [PDF]

				D. E. Geller, M. Rosenfeld, D. A. Waltz, and R. W. Wilmott Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System Chest, January 1, 2003; 123(1): 28 - 36. [Abstract] [Full Text] [PDF]

				D. E. Geller, W. H. Pitlick, P. A. Nardella, W. G. Tracewell, and B. W. Ramsey Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis* Chest, July 1, 2002; 122(1): 219 - 226. [Abstract] [Full Text] [PDF]

				P-F. Dequin, F. Faurisson, E. Lemarie, F. Delatour, S. Marchand, C. Valat, E. Boissinot, C. de Gialluly, and P. Diot Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis Eur. Respir. J., August 1, 2001; 18(2): 316 - 322. [Abstract] [Full Text] [PDF]

				S. L. Katz, S. L. Ho, and A. L. Coates Nebulizer Choice for Inhaled Colistin Treatment in Cystic Fibrosis Chest, January 1, 2001; 119(1): 250 - 255. [Abstract] [Full Text] [PDF]

				W. H. FINLAY, C. F. LANGE, M. KING, and D. P. SPEERT Lung Delivery of Aerosolized Dextran Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 91 - 97. [Abstract] [Full Text]